Aadi Bioscience Q2 FYARRO sales $6.2M, net loss $14.6M; PRECISION1 interim analysis Q3

Whitehawk Therapeutics, Inc.

2024-Q2 EPS reported -$1.22 revenue$11,532,000

FYARRO net product sales $6.2M for Q2 2024, up 15% quarter-over-quarter, flat YoY.
Net loss of $14.6M vs. $18.0M in Q2 2023; cash and investments $78.6M as of June 30, 2024.
Two-thirds interim analysis of fully enrolled PRECISION1 trial expected in Q3 2024.
Enrollment ongoing in Phase 2 trials for endometrial cancer and neuroendocrine tumors.
Cash runway expected to fund operations into Q4 2025 based on current plans.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.